Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 212-216

  Kim, Yeul Hong ^a,b   Cheong, Seong Kyoon ^c   Lee, Jee Dong ^c   Park, Jeong Sik ^c   Shin, Sang Won ^a   Kim, Jun Suk ^a  

^a Korea University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c NONE

Author keywords

Advanced gastric carcinoma; Chemotherapy; Leucovorin; UFT

Indexed keywords

FOLINIC ACID; UFT;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; STOMACH CARCINOMA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DIARRHEA; DISEASE PROGRESSION; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; REMISSION INDUCTION; STOMACH NEOPLASMS; STOMATITIS; SURVIVAL RATE; TEGAFUR; VOMITING;

EID: 0344655446     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00026     Document Type: Article

References (23)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
2. Macdonald JS, Gohmann JJ. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 1988;15(suppl 4):42-9.
3. Adashek K, Sanger J, Longmire WP. Cancer of the stomach: review of consecutive ten-year intervals. Ann Surg 1979;189:6-10.
4. Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17(suppl 2): 61-70.
5. Fujii S, Okuda H, Toide, et al. Studies on the fate of FT-207, an antitumor agent; absorption, tissue distribution, and excretion. Pharmacokinetics 1974;8:589-94.
6. Fujii S, Ikenaka K, Fukushima M, et al. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gan To Kagaku Ryoho 1978;69: 763-72.
7. Taguchi T, Nakano Y, Jikuya K, et al. Effect of uracil on the antitumor activity of Futraful. Jpn J Cancer Chemother 1978;5: 1161-5.
8. Ikenaka K, Shirasaka T, Kitani S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Can To Kagaku Ryoho 1979;70: 353-9.
9. Muggia FM, Jeffers S, Leichman CG, et al. Potential for uracil + Ftorafur (UFT) to mimic protracted infusions of 5-fluorouracil (FU) [Abstract]. Proc Am Soc Clin Oncol 1992;11:135.
10. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10: 896-903.
11. Broker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of colorectal carcinoma. J Clin Oncol 1994;12:14-20.
12. Saltz L, Young C, Currie V, et al. Phase I and clinical pharmacologie studies of oral UFT alone and with oral leucovorin (LV) [Abstract]. Proc Am Soc Clin Oncol 1993;12:149.
13. Jaiyesimi I, Pazdur R, Ho DH, et al. Phase I trial of UFT (Ftorafur plus uracil) and leucovorin: 28 day schedule [Abstract]. Proc Am Soc Clin Oncol 1993;12:152.
14. Spicer D, Muggia F, Tulpule A, et al. Phase I arcadian dosing of daily oral uracil (U) plus 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) with leucovorin (LV) [Abstract]. Proc Am Soc Clin Oncol 1991;10:118.
15. Muggia FM, Jeffers S, Leichman CG, et al. Potential for uracil + Ftorafur to mimic protracted infusions of 5-fluorouracil [Abstract]. Proc Am Soc Clin Oncol 1992;11:135.
16. Pazdur R, Lassere T, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-300.
17. Maehara Y, Kusumoto T, Kusumoto H, Anai H, Sugimachi K. UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexyl-carbamoyl-5-fluorouracil. Chemother 1988;34:484-9.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
19. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
20. O'Connell MJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited. J Clin Oncol 1992;10:515-6.
21. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemo Pharm 1988;22:333-8.
22. Moertel CG. The natural history of advanced gastric cancer. Surg Gynecol Obstet 1968;126:1071-4.
23. Bedikian AY, Chen TT, Khankhanian N, et al. The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 1984;2:305-10.